MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demo

EQS-News: MorphoSys AG / Key word(s): Study resultsMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction 20.11.2023 / 22:29 CET/CESTThe issuer is solely responsible for the content of this a...

Related Keywords

Planegg , Bayern , Germany , Massachusetts , United States , Boston , California , San Diego , American , Thomas Biegi , Julia Neugebauer , Eamonn Nolan , Jean Paul Kress , Twitter , Linkedin , Lymphoma Society , Dynamic International Prognostic Scoring System , American Society For Hematology , Constellation Pharmaceuticals Inc , Drug Administration , Nasdaq , Exchange Commission , Distribution Services , European Medicines Agency , Spleen Volume Reduction , Strong Positive Trend , Symptom Reduction , Chief Executive Officer , Spleen Volume , Meaningful Improvements , Ruxolitinib Combination Was , Meeting Oral , American Society , Annual Meeting , New Drug Application , Marketing Authorization Application , Fast Track , Morphosy Annual Report , Corporate News , Regulatory Announcements ,